RedHill Advances Opaganib as Potential Ebola Treatment Amid Rare Bundibugyo Virus Outbreak
TEL AVIV, Israel and RALEIGH, N.C., June 2, 2026 RedHill Biopharma has announced efforts to advance the clinical development...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
TEL AVIV, Israel and RALEIGH, N.C., June 2, 2026 RedHill Biopharma has announced efforts to advance the clinical development...
VENLO, Netherlands & GERMANTOWN, Md., May 28, 2026 QIAGEN announced the availability of two custom-designed research-use-only (RUO) QIAcuity digital...
TARRYTOWN, N.Y. | May 28, 2026 Regeneron Pharmaceuticals announced that maftivimab, the lead neutralizing antibody within its FDA-approved Ebola...
